Rational Drug Design

Novel Methodology and Practical Applications

Abby L. Parrill, EDITOR
University of Memphis

M. Rami Reddy, EDITOR
Metabasis Therapeutics, Inc.

American Chemical Society
# Contents

<table>
<thead>
<tr>
<th>Preface</th>
<th>xi</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. <strong>Overview of Rational Drug Design</strong>&lt;br&gt;M. Rami Reddy and Abby L. Parrill</td>
<td>1</td>
</tr>
<tr>
<td>4. <strong>Binding Evaluation Using the Finite Difference Solution to the Linearized Poisson–Boltzmann Equation and Solvation Entropy Correction</strong>&lt;br&gt;Jian Shen</td>
<td>53</td>
</tr>
<tr>
<td>5. <strong>SmoG: A Ligand Design Method Based on Knowledge-Based Parametrization of a Solvent Reorganization Model</strong>&lt;br&gt;Robert S. DeWitte and Eugene I. Shakhnovich</td>
<td>70</td>
</tr>
<tr>
<td>6. <strong>The Evaluation of Multi-Body Dynamics for Studying Ligand–Protein Interactions: Using MBO(N)D to Probe the Unbinding Pathways of Cbz-Val-Phe-Phe-Val-Cbz from the Active Site of HIV-1 Protease</strong>&lt;br&gt;Donovan N. Chin, David N. Haney, Katya Delak, Hon M. Chun, and Carlos E. Padilla</td>
<td>87</td>
</tr>
<tr>
<td>7. <strong>Calculation of Relative Hydration Free Energy Differences for Heteroaromatic Compounds: Use in the Design of AMP Deaminase Inhibitors</strong>&lt;br&gt;Mark D. Erion and M. Rami Reddy</td>
<td>107</td>
</tr>
<tr>
<td>10. <strong>Building a Hypothesis for Nucleotide Transport Inhibitors</strong>&lt;br&gt;K. Raghavan, Scott D. Kahn, and John K. Buolamwini</td>
<td>153</td>
</tr>
<tr>
<td>11. <strong>Unified Pharmacophoric Model for Cannabinoids and Aminoalkylindoles Derived from Molecular Superimposition of CB₁ Cannabinoid Receptor Agonists CP55244 and WIN55212-2</strong>&lt;br&gt;Joong-Youn Shim, Elizabeth R. Collantes, William J. Welsh, and Allyn C. Howlett</td>
<td>165</td>
</tr>
</tbody>
</table>
12. Structure-Based Design of Novel Conformationally Restricted HIV Protease Inhibitors
   B. G. Rao, C. T. Baker, J. T. Court, D. D. Deininger,
   J. P. Griffith, E. E. Kim, J. L. Kim, B. Li, S. Pazhanisamy,
   F. G. Salituro, W. C. Schairer, and R. D. Tung
   185

   A. Tropsha, S. J. Cho, and W. Zheng
   198

14. Molecular Hologram QSAR
   Trevor W. Heritage and David R. Lowis
   212

15. Adapting Structure-Based Drug Design in the Paradigm of Combinatorial Chemistry and High-Throughput Screening: An Overview and New Examples with Important Caveats for Newcomers to Combinatorial Library Design Using Pharmacophore Models or Multiple Copy Simultaneous Search Fragments
   Arup K. Ghose, Vellarkad N. Viswanadhan and John J. Wendoloski
   226

16. The Basic Shape Topology of Protein Interfaces
   John Lawton, Melanie Tudor, and W. Todd Wipke
   239

   David E. Clark
   255

18. Further Development of a Genetic Algorithm for Ligand Docking and Its Application to Screening Combinatorial Libraries
   Gareth Jones, Peter Willett, Robert C. Glen, Andrew R. Leach, and Robin Taylor
   271

19. Reduced Dimensionality in Ligand-Protein Structure Prediction: Covalent Inhibitors of Serine Proteases and Design of Site-Directed Combinatorial Libraries
   Daniel K. Gehlhaar, Djamal Bouzida, and Paul A. Rejto
   292

20. Development and Validation of the EVA Descriptor for QSAR Studies
   David B. Turner, Peter Willett, Allan M. Ferguson, and Trevor W. Heritage
   312

21. PRO_ANALOG: Automated Analog Building According to Principles of Medicinal Chemistry
   Richard G. A. Bone, Michael A. Firth, Richard A. Sykes, Christopher W. Murray, and Jin Li
   330

22. Is Rational Design Good for Anything?
   Donald B. Boyd
   346

Author Index
   357

Subject Index
   358